Table 4.
Author |
PPIs |
H2RAs |
||||||||||
Number of |
Healing rate ( ITT ) |
Number of |
Healing rate ( ITT ) |
|||||||||
Drug | Dose | Patient | 4 wk | 8 wk | 12 wk | Drug | Dose | Patient | 4 wk | 8 wk | 12 wk | |
sd PPIs vs sd H2RA | ||||||||||||
Feldman (55) | Lan | 30 o.d. | 61 | 54/61 | Ran | 150 b.d. | 32 | 12/32 | ||||
Sontag (56) | Lan | 30 o.d. | 105 | 75/105 | 84/105 | Ran | 150 b.d. | 54 | 28/54 | 16/541 | ||
Pooled data | 166 | 75/105 | 138/166 | 86 | 28/54 | 28/86 | ||||||
Pooled rate (%) | 71.4 | 83.1 | 51.9 | 32.6 | ||||||||
hd PPIs vs hd H2RA | ||||||||||||
Lundell (57) | Ome | 40 o.d. | 51 | 32/51 | 35/51 | 46/51 | Ran | 300 b.d. | 47 | 8/47 | 18/47 | 22/47 |
Ome: omeprazole; Lan: lansoprazole; Ran: ranitidine; o.d.: once daily in the morning; b.d.: twice daily; h.d.: high dose; sd: standard dose. This study did not report cumulative healing rate at 8 wk. All patients’ endpoint was at 8 wk. The decreased healing rate at 8 wk for ranitidine group may be due to subsequent relapse of esophagitis.